Migraine Trial, Recruiting NCT06549270 Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06549270
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman between 18 and 75 years old
  • You have been diagnosed with episodic migraine or chronic migraine (based on standard international diagnostic guidelines)
  • If you have episodic migraine, you have had between 8 and 14 migraine days per month over the past 3 months
  • Your migraine is considered treatment-resistant, meaning you have tried and not responded to at least 3 different types of migraine prevention medications, and you have had at least 8 severely debilitating headache days per month for at least 3 months in a row
  • You have never previously been treated with medications that target CGRP (a protein involved in migraine) (confirm with trial site)

Who may not be able to join:

  • You have a history of major mental health conditions or other neurological (brain or nervous system) conditions
  • You have been diagnosed with other types of headache disorders, apart from occasional tension-type headaches where you can clearly tell the difference between those and your migraines
  • You have made changes to any ongoing migraine prevention treatment within the past 3 months
  • You have other significant medical conditions that could affect your health or participation (confirm with trial site)
  • You have a long-term chronic pain condition
  • You have a history of alcohol or drug misuse
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 00390382380425

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Registry
ClinicalTrials.gov
Start date
10 May 2023
Est. completion
1 February 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Gene expression of FAAH; Gene expression of MAGL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov